Journal of Diabetes最新文献

{"title":"Changes in the prevalence of diabetes and control of risk factors for diabetes among Chinese adults from 2007 to 2017: An analysis of repeated national cross-sectional surveys","authors":"Chenye Jin,&nbsp;Yaxin Lai,&nbsp;Yongze Li,&nbsp;Di Teng,&nbsp;Wenying Yang,&nbsp;Weiping Teng,&nbsp;Zhongyan Shan,&nbsp;For the China National Diabetes and Metabolic Disorders Study Group and the Thyroid Disorders, Iodine Status and Diabetes Epidemiological Survey Group","doi":"10.1111/1753-0407.13492","DOIUrl":"10.1111/1753-0407.13492","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>To examine changes in the prevalence of diabetes and the control of risk factors for diabetes over 10 years among adults in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two population-based cross-sectional surveys were used to obtain a nationally representative sample of adults aged 20 years and older in mainland China in 2007 (<i>n</i> = 46 239) and 2017 (<i>n</i> = 73 340). Changes in the prevalence of diabetes, impaired fasting glucose, impaired glucose tolerance, and prediabetes, as diagnosed by the World Health Organization criteria, were assessed over time.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The weighted prevalence of diagnosed diabetes (3.8% vs 6.3%, <i>p</i> = .0001) and total diabetes (9.7% vs 11.7%, <i>p</i> = .005) increased among the overall population between 2007 and 2017. The weighted prevalence of undiagnosed diabetes (5.9% vs 5.4%, <i>p</i> = .7), impaired fasting glucose (2.7% vs 2.6%, <i>p</i> = .68), impaired glucose tolerance (12.7% vs 12.5%, <i>p</i> = .95), prediabetes (15.4% vs 15.1%, <i>p</i> = .79), the treatment of diabetes (34.1% vs 32.5%, <i>p</i> = .44), and the control of diabetes (31.1% vs 32.8%, <i>p</i> = .73) did not significantly change over this period. The awareness of diabetes (39.4% vs 53.6%, <i>p</i> = .0004) increased over 10 years among the overall population. The proportion of achieved high-density lipoprotein cholesterol targets increased (<i>p</i> = .005), but the proportion of achieved body mass index (<i>p</i> = .01) and waist circumference (<i>p</i> = .0002) targets decreased significantly.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Between 2007 and 2017, the prevalence of total diabetes (diagnosed by the World Health Organization criteria), especially diagnosed diabetes, increased among adults in China. Although awareness of diabetes improved, effective interventions and clinical strategies are urgently required.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13492","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71476016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial","authors":"Liam Mc Morrow,&nbsp;Frauke Becker,&nbsp;Ruth L. Coleman,&nbsp;Hertzel C. Gerstein,&nbsp;Lars Rydén,&nbsp;Stefan Schöder,&nbsp;Alastair M. Gray,&nbsp;Jose Leal,&nbsp;Rury R. Holman,&nbsp;for the ACE Study Group","doi":"10.1111/1753-0407.13473","DOIUrl":"10.1111/1753-0407.13473","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The Acarbose Cardiovascular Evaluation (ACE) trial (ISRCTN91899513) evaluated the alpha-glucosidase inhibitor acarbose, compared with placebo, in 6522 patients with coronary heart disease and impaired glucose tolerance in China and showed a reduced incidence of diabetes. We assessed the within-trial medical resource use and costs, and quality-adjusted life years (QALYs).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Resource use data were collected prospectively within the ACE trial. Hospitalizations, medications, and outpatient visits were valued using Chinese unit costs. Medication use was measured in drug days, with cardiovascular and diabetes drugs summed across the trial by participant. Health-related quality of life was captured using the EuroQol-5 Dimension-3 Level questionnaire. Regression analyses were used to compare resource use, costs, and QALYs, accounting for regional variation. Costs and QALYs were discounted at 3% yearly.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Hospitalizations were 6% higher in the acarbose arm during the trial (rate ratio 1.06, <i>p</i> = .009), but there were no significant differences in total inpatient days (rate ratio 1.04, <i>p</i> = .30). Total costs per participant, including study drug, were significantly higher for acarbose (¥ [Yuan] 56 480, £6213), compared with placebo (¥48 079, £5289; mean ratio 1.18, <i>p</i> &lt; 0.001). QALYs reported by participants in the acarbose arm (3.96 QALYs) were marginally higher than in the placebo arm (3.95 QALYs), but the difference was not statistically significant (0.01 QALYs; <i>p</i> = .58).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Acarbose, compared with placebo, participants cost more due to study drug costs and reported no statistically significant difference in QALYs. These higher within-trial costs could potentially be offset in future by savings from the acarbose-related lower incidence of diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13473","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71418861","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Associations of concurrent early-life famine exposure and adulthood obesity with type 2 diabetes mellitus in middle-aged Chinese","authors":"Qian Yi,&nbsp;Jing Wu,&nbsp;Yaojia Shen,&nbsp;Yunying Zhu,&nbsp;Yiyang Zhou,&nbsp;He Bai,&nbsp;Jiajun Hao,&nbsp;Peige Song","doi":"10.1111/1753-0407.13480","DOIUrl":"10.1111/1753-0407.13480","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Evidence has shown that early-life famine exposure and obesity in adulthood are independently associated with the risk of type 2 diabetes mellitus (T2DM). However, few studies had revealed the combined effect of these risk factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Two sets of groups from the China Health and Retirement Longitudinal Study (CHARLS) were selected. The fetal-exposure group born in 1959–1961 from 2011 wave (<i>N</i> = 958) and nonexposure group born in 1963–1965 from 2015 wave (<i>N</i> = 1540) were selected as Comparison 1. The early childhood-exposure group born in 1955–1957 from 2011 wave (<i>N</i> = 1510) and fetal-exposure group born in 1959–1961 from 2015 wave (<i>N</i> = 943) were Comparison 2. Logistic regressions were applied to examine the associations of different famine exposure periods and obesity patterns with T2DM risk.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Compared with nonexposed participants without central overweight/obesity in adulthood, central overweight/obesity in adulthood together with nonexposure (odds ratio [OR]: 1.89, 95% confidence interval [CI]: 1.19–3.00) or fetal-exposure (OR: 1.99, 95% CI: 1.23–3.23) was associated with higher risks of T2DM. Compared with the early childhood-exposure group, the fetal-exposed participants showed higher risks of T2DM (OR: 1.30, 95% CI: 1.02–1.66). The coexistence of fetal famine exposure and central overweight/obesity in adulthood was associated with higher risks of T2DM (OR: 1.82, 95% CI: 1.19–2.79). Consistent associations were observed among males and participants from less severely affected areas.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In conclusion, central overweight/obesity in adulthood is associated with the increased risk of T2DM, but the effect of early-life famine exposure is not very clear.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13480","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50160104","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The efficacy and safety of beinaglutide alone or in combination with insulin glargine in Chinese patients with type 2 diabetes mellitus who are inadequately controlled with oral antihyperglycemic therapy: A multicenter, open-label, randomized trial","authors":"Xiangyang Liu,&nbsp;Wenjuan Yang,&nbsp;Jianrong Liu,&nbsp;Xinxi Huang,&nbsp;Yujie Fang,&nbsp;Jie Ming,&nbsp;Jingbo Lai,&nbsp;Jianfang Fu,&nbsp;Qiuhe Ji,&nbsp;Li Wang","doi":"10.1111/1753-0407.13483","DOIUrl":"10.1111/1753-0407.13483","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To compare glycemic control in Chinese patients with type 2 diabetes mellitus (T2DM) whose blood glucose levels were inadequately controlled with oral antidiabetic drugs after beinaglutide alone or combined with insulin glargine (IGlar).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In this 16-week multicenter, randomized clinical trial, 68 participants randomly received beinaglutide or IGlar for 8 weeks, then the two drugs in combination for 8 weeks. The primary outcomes were the proportion of individuals achieving their glycemic target and the change in glucose variability as measured with a continuous glucose monitoring system from baseline to 8 and 16 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both the beinaglutide and IGlar groups showed increased proportions achieving their glycemic target at 8 weeks, and the combination augmented the proportion reaching the glycated hemoglobin target from 25.42% at 8 weeks to 40.68% at 16 weeks. The beinaglutide group showed a significant reduction in body weight, body mass index, waist circumference, and systolic blood pressure. Beinaglutide elevated high-density lipoprotein cholesterol by 0.08 mmol/L (95% confidence interval [CI], 0.00–0.16), and diminished low-density lipoprotein cholesterol by 0.21 mmol/L (95% CI, 0.05–0.48), whereas IGlar showed no effect. Though IGlar was more efficient in lowering fasting plasma glucose than beinaglutide at comparable efficacies (to −1.57 mmol/L [95% CI, −2.60 to −0.54]), this difference was abolished in patients whose fasting C-peptide was ≥0.9 ng/mL.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Beinaglutide exhibited a favorable hypoglycemic effect on patients with T2DM, and in combination with IGlar, glucose level was further decreased. Low fasting C-peptide in patients may reduce the glycemic response to beinaglutide therapy. We recommend that C-peptide levels be evaluated when using or switching to the novel glucagon-like peptide-1 receptor agonists beinaglutide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>ClinicalTrials.gov: NCT03829891.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13483","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49672112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of changes in glycemic control and diabetic complications over time and factors associated with the progression of diabetic complications in Japanese patients with juvenile-onset type 1 diabetes mellitus","authors":"Takafumi Masuda,&nbsp;Naoto Katakami,&nbsp;Hirotaka Watanabe,&nbsp;Naohiro Taya,&nbsp;Kazuyuki Miyashita,&nbsp;Mitsuyoshi Takahara,&nbsp;Ken Kato,&nbsp;Akio Kuroda,&nbsp;Munehide Matsuhisa,&nbsp;Iichiro Shimomura","doi":"10.1111/1753-0407.13486","DOIUrl":"10.1111/1753-0407.13486","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>This study aimed to evaluate the changes in glycemic control and diabetic complications over time in Japanese patients with juvenile-onset type 1 diabetes mellitus and to clarify the factors associated with the progression of diabetic complications.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We tracked 129 patients with type 1 diabetes mellitus (21.8 ± 4.1 years old [mean ± SD] with a diabetes duration of 12.6 ± 5.7 years) for up to 19 years and analyzed data on glycated hemoglobin (HbA1c) and indicators related to the severity of diabetic complications (estimated glomerular filtration rate [eGFR], urinary albumin excretion rate [UAE], carotid intima-media thickness [CIMT], and brachial-ankle pulse wave velocity [baPWV]) using linear mixed model and decision tree analysis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Although the HbA1c and UAE levels improved over time, the eGFR, CIMT, and baPWV worsened. Decision tree analysis showed that HbA1c and the glycoalbumin/HbA1c ratio for eGFR; HbA1c and systolic blood pressure for UAE; low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio, glycoalbumin/HbA1c ratio, and body mass index (BMI) for CIMT; and HbA1c for baPWV were associated factors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In this retrospective observational study, glycemic control and albuminuria improved; however, renal function and arteriosclerosis worsened over time. HbA1c levels, glycemic excursion, and blood pressure are associated with nephropathy progression. HbA1c levels, glycemic excursion, lipid levels, and BMI are associated with the progression of atherosclerosis.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13486","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49672110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of chiglitazar on glycemic control in type 2 diabetic patients with metabolic syndrome and insulin resistance: A pooled data analysis from two phase III trials","authors":"Zhiqiang Ning,&nbsp;Guoqiang Ai,&nbsp;Bo Chen,&nbsp;He Yao,&nbsp;Haixiang Cao,&nbsp;Desi Pan,&nbsp;Xianping Lu","doi":"10.1111/1753-0407.13484","DOIUrl":"10.1111/1753-0407.13484","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>To evaluate the glycemic control effects of vhiglitazar (carfloglitazar), a novel peroxisome proliferator-activated receptor pan-agonist, in patients with type 2 diabetes mellitus (T2DM) with metabolic syndrome (MetS) or insulin resistance (IR) using pooled data analysis of two phase III clinical trials.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data were collected from two randomized phase III clinical trials in China, comparing chiglitazar to placebo or sitagliptin in T2DM patients. The MetS was defined by the Adult Treatment Panel III MetS criteria, and IR was defined by homeostatic model assessment for insulin resistance (HOMA-IR) ≥4.31 (male) or 4.51 (female). The main end point of this analysis was glycemic control in the different arms within each subgroup.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the MetS subgroup, changes in glycated hemoglobin (HbA1c) from baseline at week 24 in the chiglitazar 32 mg, chiglitazar 48 mg, and sitagliptin 100 mg arms were −1.44%, −1.68%, and −1.37%, respectively; <i>p</i> &lt; .05 was obtained when chiglitazar 48 mg was compared with sitagliptin. In the IR subgroup, the changes in HbA1c were −1.58%, −1.56%, and −1.26% in chiglitazar 32 mg, chiglitazar 48 mg, and sitagliptin 100 mg arms, respectively; <i>p</i> &lt; .05 was obtained when chiglitazar 32 mg was compared with sitaligptin. The two doses of chiglitazar demonstrated a greater reduction in fasting plasma glucose and 2 h postprandial plasma glucose than sitagliptin in the pooled population and in the MetS and IR subgroups.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Chiglitazar shows promising efficacy for glycemic control in patients with T2DM associated with MetS or IR. Further prospective trials are required to validate these findings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13484","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49672111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Washed microbiota transplantation reduces glycemic variability in unstable diabetes","authors":"Yangyang Li,&nbsp;Qing Liu,&nbsp;Lingyu Zhang,&nbsp;Jing Zou,&nbsp;Rongbo He,&nbsp;Ying Zhou,&nbsp;Chen Qian,&nbsp;Yuxiao Zhu,&nbsp;Rourou Chen,&nbsp;Ying Zhang,&nbsp;Pengpeng Cai,&nbsp;Miao Wang,&nbsp;Wei Shao,&nbsp;Minjun Ji,&nbsp;Hao Wu,&nbsp;Faming Zhang,&nbsp;Zejian Liu,&nbsp;Yu Liu","doi":"10.1111/1753-0407.13485","DOIUrl":"10.1111/1753-0407.13485","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Dysbiosis of gut microbiota is causally linked to impaired host glucose metabolism. We aimed to study effects of the new method of fecal microbiota transplantation, washed microbiota transplantation (WMT), on reducing glycemic variability (GV) in unstable diabetes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Fourteen eligible patients received three allogenic WMTs and were followed up at 1 week, 1 month, and 3 months. Primary outcomes were daily insulin dose, glucose excursions during meal tests, and GV indices calculated from continuous monitoring or self-monitoring glucose values. Secondary outcomes were multiomics data, including 16S rRNA gene sequencing, metagenomics, and metabolomics to explore underlying mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Daily insulin dose and glucose excursions markedly dropped, whereas GV indices significantly improved up to 1 month. WMT increased gut microbial alpha diversity, beta diversity, and network complexity. Taxonomic changes featured lower abundance of genera <i>Bacteroides</i> and <i>Escherichia</i>-<i>Shigella</i>, and higher abundance of genus <i>Prevotella</i>. Metagenomics functional annotations revealed enrichment of distinct microbial metabolic pathways, including methane biosynthesis, citrate cycle, amino acid degradation, and butyrate production. Derived metabolites correlated significantly with improved GV indices. WMT did not change circulating inflammatory cytokines, enteroendocrine hormones, or C-peptide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>WMT showed strong ameliorating effect on GV, raising the possibility of targeting gut microbiota as an effective regimen to reduce GV in diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13485","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41230968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ten-year clinical characteristics of patients with early-onset type 2 diabetes: A single-center experience in China","authors":"Ruiqi Yu,&nbsp;Xiaoyu Liu,&nbsp;Ruochen Li,&nbsp;Xinhua Xiao","doi":"10.1111/1753-0407.13477","DOIUrl":"10.1111/1753-0407.13477","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aims</h3>\u0000 \u0000 <p>The incidence of type 2 diabetes in China has exhibited an increasing trend, including younger individuals, over the past years. Early-onset type 2 diabetes (EOT2D) refers to diabetes diagnosed before 40 years of age. These patients have poor metabolic control and are highly susceptible to diabetic complications, which poses challenges for treatment. However, few studies have reported on the treatment of EOT2D. We determined clinical features and trends in drug use in patients with type 2 diabetes mellitus (T2DM).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Materials and Methods</h3>\u0000 \u0000 <p>This retrospective study was performed at the Endocrinology Ward, Peking Union Medical College Hospital (PUMCH). “Diabetes” was used when searching PUMCH's Electronic Medical Record Analytical Database to obtain clinical data of patients between January 2013 and May 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The analysis included 1590 patients with T2DM. Among them, 609 (38.3%) had EOT2D. Compared with late-onset type 2 diabetes (LOT2D) patients, EOT2D patients exhibited worse glycemic control and higher body weight and lipid levels despite significant age differences. EOT2D patients also had a higher risk of diabetic retinopathy and nephropathy. Under the general trend of increasing use of dipeptidylpeptidase-4 inhibitors, sodium-glucose cotransporter-2 inhibitors, and glucagon-like peptide-1 agonists, patients with EOT2D were more likely to use organ-protective drugs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Compared with LOT2D patients, EOT2D patients have a longer course of diabetes, worse metabolic control, and a higher rate of developing microvascular complications. The administration of combined therapy, including new agents, may require consideration when selecting hypoglycemic agents for treating EOT2D.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 1","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13477","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41092431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adrenal limb thickness is associated with metabolism profiles in patients with diabetes: A cross-sectional study","authors":"Yingning Liu,&nbsp;Xiantong Zou,&nbsp;Wei Zhao,&nbsp;Xun Yao,&nbsp;Lexuan Wang,&nbsp;LingLi Zhou,&nbsp;Rui Zhang,&nbsp;Yingying Luo,&nbsp;Meng Li,&nbsp;Xiuying Zhang,&nbsp;Yu Zhu,&nbsp;Xiaoling Cai,&nbsp;Xianghai Zhou,&nbsp;Xueyao Han,&nbsp;Linong Ji","doi":"10.1111/1753-0407.13479","DOIUrl":"10.1111/1753-0407.13479","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The association between adrenal size and metabolic profiles in patients with diabetes mellitus (DM) is unclear. This study was conducted to determine whether the adrenal thickness measured by computed tomography (CT) is correlated with the metabolic profiles of patients with DM.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a cross-sectional study including 588 Chinese hospitalized patients with DM without comorbidities or medications known to affect adrenal morphology or hormone secretion. Adrenal limb thickness was measured on unenhanced chest CT. Participants were stratified into tertiles according to their total adrenal limb thickness. Linear and logistic regression models were used to estimate the correlations.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>After adjustment for sex and age, the adrenal thickness was positively associated with body mass index (BMI), waist circumference (WC), urinary albumin/creatinine ratio, and 24-h urinary free cortisol (UFC) and negatively correlated with high-density lipoprotein cholesterol. The sequential equation model (SEM) suggested UFC partially mediated the effect of adrenal limb thickness on WC by 12%. Adrenal thickness, but not UFC, was associated with a higher risk of existing hypertension (odds ratio [OR] = 3.78, 95% confidence interval [CI] 1.58, 9.02) and hyperlipidemia (OR = 2.76, 95% CI 1.03, 7.38), independent of age, gender, BMI, and WC.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The adrenal thickness is independently associated with BMI, WC, cortisol levels, urinary albumin/creatinine ratio, hypertension, and dyslipidemia but not glycemic parameters in patients with diabetes. Our study encourages further studies to investigate the role of adrenal physiology in patients with diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"16 2","pages":""},"PeriodicalIF":4.5,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13479","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41096402","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risks and benefits of vaccines in diabetes","authors":"Zachary Bloomgarden","doi":"10.1111/1753-0407.13481","DOIUrl":"10.1111/1753-0407.13481","url":null,"abstract":"&lt;p&gt;We are approaching 4 years from the onset of the COVID-19 pandemic, and it is appropriate to review the topic of recommended vaccines for persons with diabetes. Infections are important causes of adverse outcome among persons with diabetes and are associated with morbidity and mortality substantially above rates among persons not having diabetes. Analysis of &gt;500 000 UK Biobank participants showed that diabetes was associated with 1.5-fold and 1.8-fold greater COVID mortality in women and in men, respectively, but also with 2.2-fold and 1.9-fold greater influenza/pneumonia mortality in women and in men.&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The 2014 US Medical Expenditure Panel Surveys, representing 24 million persons with and 218 million without diabetes, showed that diabetes was associated with nearly a doubling in the likelihood of pneumonia and with a 2.6-fold increase in hospitalization for pneumonia.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Diabetes was associated with a nearly 4-fold increase in likelihood of herpes zoster,&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; with these infections in turn associated with increases in myocardial infarction (MI) and stroke.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; The response of “social media” to COVID, however, has been associated with considerable misinformation about many healthcare recommendations.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; Many of my patients now question the benefit of routinely recommended vaccination to prevent influenza, COVID-19, pneumonia, zoster, and the many other infections for which effective preventative measures are available. We will review some of these considerations and how they apply to the treatment of diabetes.&lt;/p&gt;&lt;p&gt;A number of vaccines are considered “must-haves” for people with diabetes: vaccines for influenza, COVID-19, hepatitis B, pneumococcal pneumonia, tetanus, and at age 50 or greater herpes zoster.&lt;span&gt;&lt;sup&gt;6&lt;/sup&gt;&lt;/span&gt; New vaccines being developed may be appropriate, for example, that for respiratory syncytial virus (RSV).&lt;span&gt;&lt;sup&gt;7&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt;&lt;p&gt;For influenza vaccination, manufacturer product information in studies of &lt;2000 persons receiving vaccine versus placebo, most not having diabetes or other medical conditions, suggests moderate efficacy of 68% in reducing infection.&lt;span&gt;&lt;sup&gt;8&lt;/sup&gt;&lt;/span&gt; There is evidence of benefit in at-risk persons such as those with diabetes. An epidemiologic study of vaccinated persons with diabetes showed a 46% lower mortality than among those not vaccinated and an 11% lower rate of hospitalization for pneumonia.&lt;span&gt;&lt;sup&gt;9&lt;/sup&gt;&lt;/span&gt; In two studies from Taiwan, one of persons with chronic kidney disease (CKD) not known to have underlying (Cardiovascular disease (CVD) showed that those who had received one, two, three, and four influenza vaccines between 1997 and 2008 had likelihood of acute coronary syndrome reduced 38%, 61%, and 87% in comparison to those who had not received the vaccine,&lt;span&gt;&lt;sup&gt;10&lt;/sup&gt;&lt;/span&gt; and another study of persons with CKD showed &gt; 50% red","PeriodicalId":189,"journal":{"name":"Journal of Diabetes","volume":"15 10","pages":"806-807"},"PeriodicalIF":4.5,"publicationDate":"2023-09-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/1753-0407.13481","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41092810","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}